Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYTO NK-102
- Development stage
- Unknown
- Lead developer
- CytoImmune Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CYTO NK-102 is an allogeneic, off-the-shelf natural killer (NK) cell therapy developed by CytoImmune Therapeutics for the treatment of solid tumors, specifically relapsed or refractory non-small cell lung cancer (NSCLC). Utilizing the proprietary TRACK-NK (Tumor-Reactive Adaptable Cytotoxic Killer NK) platform, these cells are engineered to express a membrane-bound form of interleukin-15 (mbIL-15). This engineering is intended to promote the persistence, survival, and anti-tumor activity of the NK cells without the requirement for exogenous cytokine administration. The therapy is designed to overcome the immunosuppressive tumor microenvironment and is being evaluated in Phase 1 clinical trials both as a monotherapy and in combination with the PD-L1 inhibitor atezolizumab.
- Other names
- TRACK-NK
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on CYTO NK-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYTO NK-102.